Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Voltaren · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc) |
| 2 | ACTIVE_COMPARATOR | Voltaren 50 mg Tablets (Geigy Pharmaceuticals) |
| Name | Type | Description |
|---|---|---|
| Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc) | DRUG | - |
| Voltaren 50 mg Tablets (Geigy Pharmaceuticals) | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: * Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.
Voltaren is used for inflammation. It is a small molecule drug being developed by Novartis AG for the treatment of inflammation. The drug is currently in Phase 1 clinical development, with one completed trial involving 38 participants.
Voltaren is developed by Novartis AG, a pharmaceutical company listed on the stock exchange under the ticker symbol NVS. The drug is being investigated for its use in treating inflammation.
Voltaren is in Phase 1 clinical development. It has completed one Phase 1 trial, which was an active-controlled study with 38 participants. The drug is still investigational and has not been approved for use.
Voltaren has one completed clinical trial with the identifier NCT00913224, titled 'To Demonstrate the Relative Bioavailability of Diclofenac Sodium 50 mg Enteric-Coated Tablets'. This Phase 1 study enrolled 38 healthy male volunteers aged 18 years and older.
Voltaren is a brand name for diclofenac sodium. The clinical trial for Voltaren specifically studied diclofenac sodium 50 mg enteric-coated tablets. The drug is being developed by Novartis AG for inflammation.